Study on bimatoprost eye solution vs tacrolimus ointment in treatment of stable vitiligo.

Comparative study on the therapeutic efficacy of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus (0.1%) ointment in stable vitiligo. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061673

Enrollment

Registered

2024-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Bimatoprost (0.03%) Ophthalmic Solution: Prostaglandin Analogue Dose- 0.03% Frequency- Twice Daily Route - Topical application over the lesions Follow up- 4 weeks, 8 weeks and 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Stable vitiligo patients involving less than 5 % of body surface area attending the dermatology OPD at Era Lucknow Medical College and Hospital

Exclusion criteria

Exclusion criteria: 1. Vitiligo patients who took treatment in last 3 months 2. Patient having hypersensitivity to tacrolimus ointment and bimatoprost ophthalmic solution. 3. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
To compare the therapeutic response of topical bimatoprost (0.03%) ophthalmic solution with tacrolimus (0.1%) ointment in cases of stable vitiligo.Timepoint: 0,4,8,12 weeks	—

Secondary

Measure	Time frame
1.To study the clinical response of bimatoprost (0.03%) ophthalmic solution on stable vitiligo. 2.To study the clinical response of tacrolimus (0.1%) ointment on stable vitiligo. 3.To identify any adverse effects associated with the use of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus ointment (0.1%) in cases of stable vitiligo. Timepoint: 0,4,8,12 weeks	—

Countries

India

Contacts

Public ContactRiya

Eras Lucknow Medical College and Hospital

drkshitijsaxena@live.com9208015391

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026